Rating Change
Stifel analysts reiterated a Buy rating on Ligand Pharmaceuticals, Inc. (OTC:LGNZZ) on July 08, 2026.
reiterateOTC:LGNZZ
Stifel Reiterates Buy Rating on Ligand Pharmaceuticals, Inc. (LGNZZ)
Rating Change Stifel analysts reiterated a Buy rating on Ligand Pharmaceuticals, Inc. (OTC:LGNZZ) on July 08, 2026. Market Context Ligand Pharmaceuticals, Inc.
Market Context
Ligand Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $0.06 with a market capitalization of $1.4M.
Analyst coverage from Stifel provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Ligand Pharmaceuticals, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Ligand Pharmaceuticals, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 08, 2026 | Stifel | Buy | N/A |
| May 08, 2026 | RBC Capital | Outperform | N/A |
| Apr 30, 2026 | HC Wainwright & Co. | Buy | N/A |
| Apr 28, 2026 | RBC Capital | Outperform | N/A |
| Apr 15, 2026 | Citigroup | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View LGNZZ Stock Page
Frequently Asked Questions
What does a Buy rating mean for LGNZZ?
A Buy rating from Stifel reflects the analyst's outlook on Ligand Pharmaceuticals, Inc. (OTC:LGNZZ). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the LGNZZ forecast page.